Rovi, a Spain-domiciled, speciality pharma company, plans to launch an enoxaparin biosimilar (originator: Sanofi Clexane/Lovenox) into key European markets by year end. Rovi currently markets Hibor (bemiparin), its proprietary second-generation low molecular weight heparin (LMWH) anticoagulant, in Spain and select international markets. We expect Rovi to benefit from the vertical integration opportunities that an enoxaparin biosimilar launch would bring as it continues to evolve into a European leader in LMWH anticoagulants.

Continue reading

This version is programmatically created by Research Central and qualified in its entirety to the original PDF.

Powered by Research Central